Sign in
CompletedNo phase

Polaprezinc (Zinc L-carnosine) in Infants With Gastroesophageal Reflux

Key facts

Who runs it
University of Roma La Sapienza
Where
Italy1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
60 people enrolled
Started
1 Dec 2024
Ended
1 Jul 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Zinc-L carnosine/Polaprezinc
  • Thickened formula
Record updated
5 May 2026

Who can take part

Age
1 month to 12 months
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (7)Hide the full registry criteria

Who can take part

  • Patients with infant regurgitation accoding to Rome IV criteria
  • Healthy infants aged 1-12 months
  • I-GERQ-R score ≥ 16 at baseline

Who cannot take part

  • Organic disease
  • Past history of preterm birth or atopy
  • Current or pregress use of pharmacological treatment for gastric acid suppression or current use of thickened formula
  • Absence of informed consent

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to evaluate efficacy and safety of Zinc-L carnosine/Polaprezinc in infants with GER.

Read full original descriptionShow less

Researchers will compare Zinc-L carnosine/Polaprezinc to a placebo (a look-alike substance that contains no drug) to see if Zinc-L carnosine/Polaprezinc works to treat infants with GER.

Participants will:

Take drug Zinc-L carnosine/Polaprezinc or a thickened formula every day for 8 weeks Visit the clinic once every 4 weeks for checkups and questionnaires

The 2 groups in the trial

  • Zinc-L carnosine/PolaprezincTreatment being tested

    This group will receive Zinc-L carnosine/Polaprezinc (Hepilor Liquido) 1 hour after meals: 2.5 ml twice a day in infants weighing \<5 kg or 5 ml twice a day in infants weighing \>5 kg.

  • Thickened formulaExisting treatment, for comparison

    Infants will receive thickened but not hydrolyzed formula

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of Polaprezinc/Zinc L-carnosine (Hepilor) in Infants With Gastroesophageal Reflux
Publications
Record updated
5 May 2026